Beckman Coulter Life Sciences, a global leader in laboratory automation, introduces the Valita Aggregation Pure assay, a groundbreaking 96-well screening tool designed to significantly reduce workflow times and manual steps. This innovative assay provides rapid, high-throughput protein aggregation detection and quantification, delivering robust data in just 15 minutes.
Traditional monoclonal antibody production workflows often require up to six hours to determine protein aggregation levels. The Valita Aggregation Pure assay offers a faster, more efficient alternative, compatible with high-performance microplate readers featuring fluorescence polarization functionality.
“Generating commercially viable cell lines involves processing thousands of samples, which can slow down laboratory workflows,” said Dr. Elisa Nent, Global Product Manager – Cell Health. “Our new assay addresses the need for rapid antibody aggregation measurement, outperforming traditional methods like DLS/SLS and HPLC-SEC. It simplifies the process, reducing manual steps, reagent requirements, and costs, all while delivering results in a fraction of the time.”
The assay enhances process development workflows by enabling rapid detection and quantification of antibody aggregation at any stage. Simply add purified samples to the plate, incubate at room temperature, and measure aggregation using a plate reader. Available in 96-well plates, it is validated for samples concentrated between 200-2,000 mg/L, with a detection limit of 0.5% aggregation at 1,000 mg/L. This enables swift, high-throughput protein aggregation analysis, making it one of the fastest and simplest tools on the market.
This article is a summary of a published press release provided by Beckman Coulter Life Sciences
